NEW YORK, May 6 - Bruker Daltonics today reported that strong first-quarter growth in its life-sciences business helped boost total revenue despite static or declining performance from other units.
Total revenue in the period ended March 31 grew to $25.7 million from $21.9 million one year ago. Of the company's total product revenues, life science systems accounted for 76 percent, up from 70 percent a year ago, Bruker said. Its substance-detection and aftermarket revenues represent 8 percent and 16 percent of product revenues this year, respectively, compared with 8 percent and 22 percent year over year.
R&D spending in the first quarter 2002 remained relatively flat at $4.5 million compared with $4.6 million reported during the same period one year ago. Total first-quarter costs and operating expenses, though, grew to $24.4 million from $21.2 million year over year.
Bruker also reported a dip in first-quarter net income to $941,000, or $.02 per share, compared with $945,000, or $.02 per share, in the first quarter 2001.
The company said it had $66.8 million in cash and short-term investments as of March 31, a slight drop from the $70.1 million it had as of Dec. 31, 2001.
For more information, click here.